Trichostatin A (TSA)

For research use only. Not for use in humans.

目录号：S1045

Trichostatin A (TSA) Chemical Structure

Molecular Weight(MW): 302.4

Trichostatin A (TSA)是一种HDAC抑制剂，无细胞试验中IC50为1.8 nM左右。

规格 价格 库存 购买数量  
RMB 2022.93 现货
RMB 3660.93 现货
RMB 7125.3 现货
有超大折扣
大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834   |   Email：info@selleck.cn

客户使用Selleck生产的Trichostatin A (TSA)发表文献113篇：

产品安全说明书

HDAC抑制剂选择性比较

生物活性

产品描述 Trichostatin A (TSA)是一种HDAC抑制剂，无细胞试验中IC50为1.8 nM左右。
靶点
HDAC [1]
(Cell-free assay)
~1.8 nM
体外研究

Trichostatin A 抑制八种乳腺癌细胞系，包括MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, 和 SK-BR-3增殖，平均IC50为124.4 nM (范围为26.4-308.1 nM),作用于表达ERα的细胞系比作用于表达 ERα阴性的细胞系更有效。Trichostatin A作用于全部乳腺癌细胞系，抑制HDAC活性，平均IC50为 2.4 nM (范围为0.6-2.6 nM), 产生显著的组蛋白 H4高度乙酰化。[1]与 Trapoxin (TPX) 和 Chlamydocin 有效抑制HDAC1 或 HDAC4而不是 HDAC6不同，Trichostatin A 抑制这些HDACs，且抑制程度相似， IC50 分别为6 nM, 38 nM, 和8.6 nM。[2] Trichostatin A (100 ng/mL) 作用于MIA PaCa-2细胞，通过招募p300和 PCAF进入Sp1-NF-Y HDAC复合体，而诱导转化生长因子βⅡ型受体(TβRII) 表达，复合体与TβRII 启动子的DNA片段结合，伴随着Sp1乙酰化，且与复合体相关的HDAC数理全部降低。[4]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK 293 M3nYfGZ2dmO2aX;uJGF{e2G7 NYP1PXIxOC55zszN NWi1fppnOjSq MmrZ[ZRp[W6xbB?= MlHM[Y5p[W6lZYOgSW5iSyCjY3X0fYxifGmxbjDhcoQhcW6lcnXhd4V{KEWQYVOgZYJ2dmSjbnPlJIlvKHSqZTD0c5RidCClZXzsJIx6e2G2ZTDhcoQh[XRidHjlJINmdGxic4Xy[oFk\Q>? NEXRWYYzPTd6N{C3PS=>
TE13 MULGeY5kfGmxbjDBd5NigQ>? NI[4d|cxNjQQvF2= Mn3tNlRp M2rlXZVxNXKnZ4XsZZRmeyCUQWPTSlVCKGyndnXs MVmyOVU4QTZ4NR?=
TE13 MYDBdI9xfG:|aYOgRZN{[Xl? M4nJblAvO87:TR?= NGHGZo8zPGh? NH7vW2NqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:w NHLGdGszPTV5OU[2OS=>
MEFs MUXGeY5kfGmxbjDBd5NigQ>? NYPFV5BRPc7:TR?= NHmxVFgyPmh? M1fmfolv[3KnYYPld{B1cGViRWDFR{BifHSjY3jt[Y51NCCWaYKg[IVtcX[ncomgZY5lKHSqZTDl[oZq[2mnbnP5JI9nKHCnZHXzeIFtKG[xcn3heIlwdg>? Ml\sNlU1QDJ4M{S=
SW480  MYHGeY5kfGmxbjDBd5NigQ>? NXHXcoQ3OC5zzszN NW\TNVk3PDiq M2fwOGROW09? M4C3c5JmfmW{c3XzJGVOXA>? M2jqUFI2PDN2OUm3
PC3  M1T1fmZ2dmO2aX;uJGF{e2G7 NUm4fY1uOC5zzszN NHvCNIw1QGh? M1O3eWROW09? M3jSXpJmfmW{c3XzJGVOXA>? NGG0bHgzPTR|NEm5Oy=>
SW480  MoP5SpVv[3Srb36gRZN{[Xl? M{\ZelAvOc7:TR?= MVe0PIg> Mn;WSG1UVw>? NIHKeHBifHSnboXheIV{KGmwdnHzbY9vKGGwZDDtbYdz[XSrb36= NVLzZ4xYOjV2M{S5PVc>
PC3  M{HLNGZ2dmO2aX;uJGF{e2G7 NWHNVHFlOC5zzszN NYPEOIdoPDiq NXrCepBETE2VTx?= NVvsWldv[XS2ZX71ZZRmeyCrbo\hd4lwdiCjbnSgcYloemG2aX;u MUiyOVQ{PDl7Nx?=
SW480  NU\xPGRPTnWwY4Tpc44hSXO|YYm= M4m5R|AvOc7:TR?= NGrwXXA1QGh? M4ntcmROW09? MoPsbY5lfWOnczDpcoNz\WG|ZTDv[kBJTEGFMTDhcoQhUESDQ{Kgc44hW2y3ZzDn[Y5meyCycn;tc5Rmeg>? M4TWb|I2PDN2OUm3
PC3  NIjlN|dHfW6ldHnvckBCe3OjeR?= MVywMlHPxE1? NGHjOG41QGh? MWHEUXNQ NGWyUVJqdmS3Y3XzJIlv[3KnYYPlJI9nKEiGQVOxJIFv\CCKRFHDNkBwdiCVbIXnJIdmdmW|IIDyc41wfGW{ MnPYNlU1OzR7OUe=
A431 M{LITmFxd3C2b4Ppd{BCe3OjeR?= MViyM|ExNzVyL{GwNI5O MoDwOFhp M{XBb2ROW09? MX7pcohq[mm2czD0bIUh[2WubDDndo94fGh? MU[yOVM4OTB4OR?=
A431 NEju[29HfW6ldHnvckBCe3OjeR?= NXrPVoxnPTCwTR?= M2DhO|IwPi9zMj:yOIg> M{nnVWROW09? NGfP[ndi[3SrdnH0[ZMheDJzIHHu[EBqdmirYnn0d{BCXEZ|IHX4dJJme3Orb36= MlO1NlU{PzFyNkm=
MDA-MB-231 MkLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTkNE03ODCwTR?= NY\vXW5SOjSq M2fZOmROW09? NYnPUIxYUUN3MDDv[kAyODCwTR?= MmjHNlUyQTJ5MkG=
MCF7 MknxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVewMVYxOG6P MWeyOIg> NVG5VVF5TE2VTx?= MXvJR|UxKG:oIEe1cm0> MWWyOVE6Ojd{MR?=
SKOV-3 NF3I[FRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVexMVEx|ryP M2r6cFI1cA>? MYfEUXNQ NXTmOZVqUUN3MDDv[kA2NjcQvF2= MYeyOVE3QTR7MR?=
A549 MkLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\5NU0yOM7:TR?= MYKyOIg> M3v4NGROW09? M4rBfGlEPTBib3[gN{4z|ryP MU[yOVE3QTR7MR?=
SKOV-3 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M336c|AvOS1zzszN M17FWFQ5cA>? NUK3NmU4TE2VTx?= M4TMTmlEPTBib3[gNE44|ryP M2LMcFI2OTZ7NEmx
A549 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{CyS|AvOS1zzszN MWK0PIg> MXzEUXNQ M3PCU2lEPTBib3[gNE4zQM7:TR?= NXLSO2JiOjVzNkm0PVE>
SKOV-3 NWLlV4lZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zqTVAvODFvMD65{txO MlnPO|Jp MkPySG1UVw>? MVzJR|UxKG:oIECuN|LPxE1? MoHlNlUyPjl2OUG=
A549 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\3O4VpOC5yMT2wMlnPxE1? Mn3OO|Jp M{LXe2ROW09? MWPJR|UxKG:oIECuNFbPxE1? MkPiNlUyPjl2OUG=
HeLa Ml\MSpVv[3Srb36gRZN{[Xl? MXOyOVBvVQ>? NVzBcHdwOT[q MnKzSG1UVw>? Mn35bY5kemWjc3XzJGN[WDGDMTDtVm5CKGW6cILld5Nqd28EoB?= MmXjNlUyOTZ4OEi=
CNE2 NWf5PGNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XvVlExOC14MEDuUS=> NV7tWZNrOjRxNEivO|Jp NGSxR5hqdmirYnn0d{B1cGVicILvcIln\XKjdHnvckBqdiCjIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M{nBTVI1QTZ7OUCx
PC3 M{fUcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2W5cVExOC1zMECwcm0> NVPB[WFHOjSq Mo\jTWM2OCCxZjCzNFBvVQ>? NEThN2czPDh3NE[1PC=>
LNCaP MonaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPobYMyODBvMUCwNI5O NWLkfGFKOjSq NWPOeHYyUUN3MDDv[kA{ODCwTR?= MlfYNlQ5PTR4NUi=
HeLa  MlLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPEbFhOOs7:TR?= MnS5OFhp M2fSUYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDhZo92fCB{NTW= NX\CUllGOjR6NE[xN|U>
HMEC-1  MVfGeY5kfGmxbjDBd5NigQ>? MoX3N|Axdk1? MYiyOIg> MYTpcoNz\WG|ZYOg[ZhxemW|c3nvckBw\sLiVlXHSnI{yqCvUl7B MnywNlQ4OTB4M{G=
HeLa NXfpcIJyTnWwY4Tpc44hSXO|YYm= MkTiNY1O NFu3emwxNjWq NULFPVN3[WKxbHnzbIV{KHSqZTD0c5RidCCKRFHDJIFkfGm4aYT5 M3nMUVI1PzB5NEe0
ACP02 M4rK[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrJe|VJOjVyL{O1NE82ODCwTR?= M1nke|I1cA>? NIXOXZJl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgc4Yh[XCycn;4bY1ifGWueTC3NOKhLSCjdDCyOVDDqG6P M1PU[|I1PjZ6NUS3
ACP03 M1HGdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUmyOVAwOzVyL{WwNI5O Moe1NlRp M1G1VIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDv[kBieHC{b4jpcYF1\Wy7IEewxsAmKGG2IEK1NOKhdk1? MVeyOFY3QDV2Nx?=
U87 GBM M{fsVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnURVZTOTByL{OwNE82ODBibl2= MUe3NkBp Ml;WNVAxLSCndHjhco9t MX7y[YR2[2W|IH3lZY4h[2WubDDueY1j\XJiYomgN|EtKDV2LDDhcoQhPTkEoDW= NFvyPGgzPDR4NEi0NS=>
U87 GBM NEjRSVVHfW6ldHnvckBCe3OjeR?= M1fnd|ExOC93MECgUo0> NYH3XYF5PDhiaB?= Ml;ONVAxLSCndHjhco9t M3LRZmlv\HWlZYOgV4Vv\XOlZX7j[U1NcWunIFHseIVz[XSrb37zJIlvKE63Y3zlZZIhVW:{cHjvcI9ogQ>? MorHNlQ1PjR6NEG=
RPE M4XEbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1ryblAvOi9yLkSvNE45NzFizszN MUmyOE81QC95MjDo NHnxZ4lFVVOR M1vueolvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJIJ6KGOnbHygZ5lkdGViYYLy[ZN1 MX:yOFQ2PjZyMh?=
HT29  NYn3VpNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfZfHQyQDBibl2= NHnoNok4OiCq MkiwTWM2OCCxZjCxPFAhdk1? M{fVRVI1OzZ6Mk[1
hMSCs MnPxSpVv[3Srb36gRZN{[Xl? NYjLbWViPi5{NTDuUS=> MWWyOEBp Mke5SG1UVw>? NHj2U3p{fGGkaXzpfoV{KEirc4TvcoUhSWOndInsZZRqd25iYX7kJJRp\SCHeIDy[ZN{cW:wIH;mJHBtfXKrcH;0[Y51KEenbnXz NFe5OGEzPDNzMkO1Oi=>
Huh7  NHvkPHlHfW6ldHnvckBCe3OjeR?= M1[1V|AvOS9yLkWvNU4xKM7:TR?= MmrVNlRp MlTSd5VxeHKnc4Pld{B[XEiGQ{Kg[4Vv\SCneIDy[ZN{cW:w NV7UUXk3OjR{Nkm2O|I>
SKOV3 MknTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnINE4xPS1{IN88US=> NF:1NY0yOC9{ND:0PEBp MXPEUXNQ MlHCcYVlcWG2ZYOg[5Jwf3SqIHHydoV{fCCrbjDhJINwdmOnboTyZZRqd25vIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? M3jDUlI1OjJ|OECx
A2780 NGKxR5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\aOlAvODVvMjFOwG0> NYLlS4dQOTBxMkSvOFghcA>? NIXNdoFFVVOR NEjOb|Vu\WSrYYTld{Boem:5dHigZZJz\XO2IHnuJIEh[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= MYqyOFIzOzhyMR?=
SRA01/04  NYTQUWM6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWOwMlIh|ryP NXvMZlN1PDhiaB?= MXTEUXNQ NGTle|Z{fXCycnXzd4V{KGOnbHygdJJwdGmoZYLheIlwdiC2aILveYdpKHO3cIDy[ZN{cW6pIITo[UBRUTONL1HreEwheDN6TVHQT{BidmRiRWLLNU8zKHOrZ37hcIlv\yCyYYToe4F6ew>? NY\MNIY3OjRzNUe4O|g>
HLEB3 NVG1WYJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWKwMlIh|ryP NXzHXIU{PDhiaB?= NG\zdnlFVVOR NXLwS5R1e3WycILld5NmeyClZXzsJJBzd2yrZnXyZZRqd25idHjyc5VocCC|dYDwdoV{e2mwZzD0bIUhWEl|Sz;Bb5QtKHB|OF3BVGsh[W6mIFXST|EwOiC|aXfuZYxqdmdicHH0bJdigXN? MnTsNlQyPTd6N{i=
SRA01/04  NYrK[mE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF24Z3cxNjRxMD64JO69VQ>? M2DIdlQ5KGh? NUjMWXJyTE2VTx?= MXLpcoR2[2W|IHPlcIwh[XCxcITvd4l{ NHPBPJEzPDF3N{i3PC=>
HLEB3 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX6wMlQwOC56IN88US=> M3\GS|Q5KGh? MkL5SG1UVw>? NFrzbWxqdmS3Y3XzJINmdGxiYYDvdJRwe2m| MnvhNlQyPTd6N{i=
HCT116 NVHRXFI3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYWwMlIh|ryP MWSxNkBp M2\CPIVvcGGwY3XzJINmdGxiYYDvdJRwe2m|IHnu[JVk\WRiYomgdoFlcWG2aX;u NXvIXZF2OjRzMkKyN|E>
CA46 M4\GVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELLfmc{NzZxMUKvNlQwPDhibl2= MmHCOFghcA>? MnzObY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdiCjdDCyOEBidmRiNEigcm3DqA>? Mn;kNlQxPjR7NUG=
PMNs NGK1bY1HfW6ldHnvckBCe3OjeR?= NXvncFh2OzBibl2= NYPQUphXPDhiaB?= MVLpcohq[mm2czDl[oZmem:leYTvd4l{NCCKRFHDJIFkfGm4aYT5JIFv\CCUYXOgZYN1cX[rdIm= MoG1NlM6QDh4MUe=
H1299 MlG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFr4b|MyyqEQvF5CpC=> MXOyOE81QC95MjDo NWnYZXFj\XSqYX7vcC=> NVuzUo8zcW6lcnXhd4V{KGOnbHyg[IVifGhiYX\0[ZIhOjSq M2nxWFI{QTF4NkC5
A549 M4LPVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIL6dIwxNjJ3L{CuOU8yKM7:TR?= MVSyOE81QC95MjDo MlTp[ZRp[W6xbB?= NIXtWXVqdmirYnn0d{B1cGViY3XscEBoem:5dHigbY4h[2:wY3XueJJifGmxbjDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ NI\EeIszOzh4N{m5NS=>
H1299 MmrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUD0VoF7OC5{NT:wMlUwOSEQvF2= NWfsNndVOjRxNEivO|IhcA>? NFPWcWtmfGijbn;s M4CySIlvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDDpckBkd26lZX70doF1cW:wIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? NFuydVczOzh4N{m5NS=>
A549 NYL3UZRzSXCxcITvd4l{KEG|c3H5 NVvMTXhsOC53L{Gg{txO M3m3OlQ5KGh? NIHBSIJmfGijbn;s MVTpcoR2[2W|IHPlcIwh[XCxcITvd4l{ NVLUbGpFOjN6Nke5PVE>
H1299 NXeyXI9pSXCxcITvd4l{KEG|c3H5 NX\ZTndxOC53L{Gg{txO MmnGOFghcA>? M4KwT4V1cGGwb3y= MUnpcoR2[2W|IHPlcIwh[XCxcITvd4l{ NEjHZm0zOzh4N{m5NS=>
SUM149PT MoTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPwNk84NjVxMUCg{txO M4rkUVQ5KGh? NEXYOFNFVVOR NFr4OJVqdmS3Y3XzJINmdGxiZHXheIgh[XRiMjFOwG0hcW6|ZX7zbZRqfmWueR?= NX;sUFFXOjN5OUK2N|g>
SUM190PT MnXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zHcVUxNzFyMD:yOVAhdk1? MofCOFghcA>? NV2x[G83TE2VTx?= MWPpcoR2[2W|IHPlcIwh\GWjdHigZZQhPTBibl2gd4Vve2m2aY\lcJk> MXqyN|c6OjZ|OB?=
HCT1 NFjZempIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTQNE4zNzFwMD:1MlAh|ryP NWPiR|lLOTJxMkSvN|YwPDhiaB?= NWDpVVA1cW6mdXPld{Bk\WyuIHTlZZRpKGmwIHPvcoNmdnS{YYTpc44uKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> MmnQNlM4PzByMEC=
Lovo MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHsUHdHOC5{L{GuNE82NjBizszN NXj6XmFNOTJxMkSvN|YwPDhiaB?= NGrNWlBqdmS3Y3XzJINmdGxiZHXheIghcW5iY3;uZ4VvfHKjdHnvck0h[W6mIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> NHLWNY4zOzd5MECwNC=>
AGS MlvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTmT3MxNjBzNT2xJO69VQ>? NXvXWXFXPzJiaB?= MlT3bY5lfWOnczDj[YxtKGSnYYToJINwdmOnboTyZZRqd25iZHXw[Y5l\W62bIm= MVGyN|c1PTB{NB?=
Huh7 NXjYVpVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmW4NUDPxE1? NEjYNlczPCCq NEL4dG9FVVOR MWry[YR2[2W|IHHic5V1KDJyJTD2bYFjcWyrdIpCpC=> MmrzNlM3PDN7M{O=
ECC1 MmXSSpVv[3Srb36gRZN{[Xl? M{\MbFUxOCCwTR?= M{nSWlUh\A>? MoTJSG1UVw>? M1PTbolv\HWlZYOgUFFESU4EoHX4dJJme3Orb36gZ48ufHKnYYTt[Y51KHerdHigOU1CgmGF M2PP[|I{PTNyN{[5
HEC1A M2PZcGZ2dmO2aX;uJGF{e2G7 NYPVO5R4PTByIH7N NF:w[|I2KGR? MlHPSG1UVw>? MXTpcoR2[2W|IFyxR2FOyqCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEWtRZpiSw>? NVX2bXNGOjN3M{C3Olk>
EN1 NE\qdJVHfW6ldHnvckBCe3OjeR?= M4T3fVUxOCCwTR?= NXnRNHh5PSCm NFjVNJdFVVOR MWDpcoR2[2W|IFyxR2FOyqCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEWtRZpiSw>? NI\DSGszOzV|MEe2PS=>
MFE296 MoXGSpVv[3Srb36gRZN{[Xl? MlHoOVAxKG6P MWG1JIQ> NInoXnVFVVOR MYnpcoR2[2W|IFyxR2FOyqCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEWtRZpiSw>? NIrXVlgzOzV|MEe2PS=>
HASMCs Mlq2SpVv[3Srb36gRZN{[Xl? NFLhdVcxNTVyMDDuUS=> MVi2JIQ> MVHkc5dvNXKnZ4XsZZRmeyC2aHWg[ZhxemW|c3nvckBw\iCKQVTDJIFv\CClZXzsJJZq[WKrbHn0fS=> NHLkUGEzOzVzOES2Oy=>
U373 M4DFSGZ2dmO2aX;uJGF{e2G7 NULMUYxzOC5{NT:wMlUwOSEQvF2= NGi2ZYkzPCCq MVrpcoNz\WG|ZYOgVHIuSiCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEXBfoFlSw>? MnLGNlM1PzRzN{G=
ARN8  NWj6UG5qTnWwY4Tpc44hSXO|YYm= NX2wVVFkOC5yNT2yJO69VQ>? M165SlI1KGh? NW\VbIpzemWmdXPld{B1cGViaX7keYN1cW:wIH;mJJA2Oy2mZYDlcoRmdnRiZ3Xu[ZMh[nliToX0cIlvNTN? MkjVNlM1PzB3NEC=
MCF7 NULr[3pETnWwY4Tpc44hSXO|YYm= M{XQXVAvODVvMjFOwG0> MmDlNlQhcA>? NELtWY9z\WS3Y3XzJJRp\SCrbnT1Z5Rqd25ib3[gdFU{NWSncHXu[IVvfCCpZX7ld{BjgSCQdYTsbY4uOw>? MljzNlM1PzB3NEC=
H1299  NITnTHNHfW6ldHnvckBCe3OjeR?= M4SwTFAvOzQkgKOxxsDDvU1? NVT4SYlQOjRxNEigbC=> NIDVS3hFVVOR MULpcoNz\WG|ZYOgSU1k[WSqZYLpckBxem:2ZXnuJIxmfmWuczDkc5NmKGSncHXu[IVvfGy7 Mo\iNlM1PjF7N{W=
H1299 MnrTSpVv[3Srb36gRZN{[Xl? NXHpd3JXOC53IN88US=> NFjlVYc1QCCq NGO4RlJFVVOR M3nJdYlvcGmkaYTzJJRp\SCvaXfyZZRwenlicH;0[Y51cWGuIHPvcYJqdmVid3n0bEB{cWyrYnnubY4> NXvidlc1OjN2NkG5O|U>
H1299 NIe2PYxHfW6ldHnvckBCe3OjeR?= MUWwMlUh|ryP NFvWfGg1QCCq MXjEUXNQ MYDpcohq[mm2czD0bIUhcW64YYPpeoVv\XO|wrCgZ49u[mmwZTD3bZRpKHOrbHnibY5qdg>? MWSyN|Q3OTl5NR?=
MG-63  NEfI[2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml64NE4{KM7:TR?= Mlz0NVIuQTZiaB?= NEPucFVFVVOR NVvYUXVFcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJINwNXS{ZXH0cYVvfCC5aYToJI1mfG[xcn3pci=> M13OOFI{PDVzOEG3
LM8 Ml\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXSwMlMh|ryP M{PyflEzNTl4IHi= NH7zcW1FVVOR NFnBc5pqdmirYnn0d{B1cGViY3XscEBoem:5dHigZ48ufHKnYYTt[Y51KHerdHigcYV1\m:{bXnu MmjzNlM1PTF6MUe=
K562 M2njV2Z2dmO2aX;uJGF{e2G7 NUDxfJE4OC53IN88US=> MWqyOEBp MlH0[ZRp[W6xbB?= M17oeoRm[3KnYYPld{B1cGViZX76fY1mKGGldHn2bZR6KG:oIFjERWN{KGOxLYTy[YF1dWWwdDD3bZRpKGO3cnP1cYlv NEfnVYMzOzR|MEm1Oy=>
HEL NYjSTVdjTnWwY4Tpc44hSXO|YYm= NEDrfIUxNjVizszN M4nWeFI1KGh? MWnleIhidm:u NH;PepZl\WO{ZXHz[ZMhfGinIHXufplu\SCjY4Tpeol1gSCxZjDISGFEeyClbz30doVifG2nboSge4l1cCCldYLjeY1qdg>? Ml3rNlM1OzB7NUe=
HL60 M3v2U2Fxd3C2b4Ppd{BCe3OjeR?= NFW0XpEyKM7:TR?= NXHjcnB4OjRiaB?= M4CwcIlv\HWlZYRCpINmdGxiZHXheIg> NIi3UJMzOzRyMEWxPS=>
KG1 MlzBRZBweHSxc3nzJGF{e2G7 NV:2eVBrOSEQvF2= MkTpNlQhcA>? M1e1b4lv\HWlZYRCpINmdGxiZHXheIg> NGTtdXIzOzRyMEWxPS=>
Kazumi MoHZRZBweHSxc3nzJGF{e2G7 M3\IZlEh|ryP MXKyOEBp MXzpcoR2[2W|wrDj[YxtKGSnYYTo MmW1NlM1ODB3MUm=
K562 M3fVdmFxd3C2b4Ppd{BCe3OjeR?= NHXSRpEyKM7:TR?= M3\jdFI1KGh? M4nBS4lv\HWlZYRCpINmdGxiZHXheIg> MX2yN|QxODVzOR?=
THP1 M2DDNWFxd3C2b4Ppd{BCe3OjeR?= MUKxJO69VQ>? M37qSlI1KGh? NU\uPZZ3cW6mdXPld:Kh[2WubDDk[YF1cA>? NIL3bHMzOzRyMEWxPS=>
SH-SY5Y MVjGeY5kfGmxbjDBd5NigQ>? MYCyOVAhdk1? NXvKZ5ZiOTZiaB?= MYTjbIFv\2W|IHX4dJJme3Orb36gdIF1fGW{bjDv[kBo\W6nczDpcpZwdH[nZDDpckBkcG:uZYP0[ZJwdCC|eX70bIV{cXNuIIXweIFs\SCjbnSg[YZndHW6 Mki5NlM{OjZ2MkK=
HEK293 MmnnSpVv[3Srb36gRZN{[Xl? M4PYcVEhyrWPwrC= M33MeVE5KGkEoB?= M4jMSolvcGmkaYTzJJRp\SCtYXzpdolvNTdvbXXkbYF1\WRicnXjdpVqfG2nboSgc4Yhe3mwcHjpcIlvNTFiYXfndoVo[XSnczDpcpRwKGGpZ4Lld49u\XN? NEPUUlUzOzJ6NEi0PC=>
HTK MmTTSpVv[3Srb36gRZN{[Xl? MkSzOFAxKG6P NVzFN|l4PzJiaB?= M3fFSYlvcGmkaYTzJHRITi4QsvMAl2lv\HWlZXSgUZlw\mmkcn;icIF{fCCGaX\m[ZJmdnSrYYTpc44> MoPrNlMzQDRyMEK=
HTK NWj1NphGTnWwY4Tpc44hSXO|YYm= MVuxNFAuQDBybl2= NVjPemJLPzJiaB?= NFvNUGpjdG:la4OgWGdHNc7{4pETTY5lfWOnZDDSU3Mh[W6mIFiyU|LDqEGlY4XteYxifGmxbh?= MkHYNlMzQDRyMEK=
Caco-2  NYXGS4R{TnWwY4Tpc44hSXO|YYm= NEfuXFkyKML3TdMg MXKyOEBp M17ZToRm[3KnYYPld{BUTVKWIIDyc5RmcW5iZYjwdoV{e2mxbh?= NU[yfJFjOjNzOUWwO|A>
HeLa NF\0VZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHSx[YcyODBibl2= NVvCZ|U{OjRiaB?= MnPsSG1UVw>? NVfxNGhpUUN3MDDv[kAyODCwTR?= M3XKd|I{OTZ3N{S4
HeLa MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY[0NEBvVQ>? M3XIOlQ5KGh? MknNSG1UVw>? NYD0endKUUN3MDDv[kA1OG6P MX[yN|E3PTd2OB?=
HeLa MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrnWZNTOjBibl2= NFXSXI44OiCq M1SxRmROW09? NWPVeWt2UUN3MDDv[kAzOG6P NUTVVJpuOjNzNkW3OFg>
HeLa M3P3VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXONVAwOzBxNUCgcm0> MYK3NkBp NYnseHdbTE2VTx?= M{jyRolv[3KnYYPld{B1cGViboXtZoVzKG:oIF3NVEAp|pUQqH2pJIxwe3NiY3XscJMh\G:|ZTDk[ZBmdmSnboTsfS=> NWTOVJluOjNzNkW3OFg>
MDA-MB-231 MkH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrFfIV7OjVvNECwJI5O M1vaOFQ5KGh? M1XodmlEPTBib3[gNlY{NjKwTdMg MWWyN|A2PTF7OB?=
MCF-7  MnzvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DDbVI2NTRyMDDuUS=> MnLlOFghcA>? M4H4dWlEPTBib3[gNlIxNjSwTR?= M3jFSlI{ODV3MUm4
ECC-1  M4DGeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzU[VdWOTByIH7N NICxeW8zPCCq Mn;q[ZRp[W6xbB?= MoXubY5kemWjc3XzJJRp\SCycn;wc5J1cW:wIH;mJIFxd3C2b4TpZ{BvfWOuZXmgeI8hOzVn MkfGNlMxOjh6MEO=
HEC-1A MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUWxNFAhdk1? NH;VZ2gzPCCq M1nWSIV1cGGwb3y= MWPpcoNz\WG|ZYOgeIhmKHC{b4DvdpRqd25ib3[gZZBweHSxdHnjJI52[2ynaTD0c{A{QSV? M3frPFI{ODJ6OECz
NHAC-kn NXjXRWJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmr1NVAwOTByL{WwNEBvVQ>? M2i0NFEzKGh? NXv2UI85TE2VTx?= MWfJR|UxKG:oIEWwNI5O NFjhZlczOzBzN{i3NS=>
A549 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI[2eGUzPTBibl2= NIrIb3I3NTd{IHi= NIm3XppFVVOR MkH1Z4F2e2W|IHGg[5Jm[XSncjDpcohq[mm2b4L5JIVn\mWldDDjc41jcW6nIIfpeIghXFiWIH;yJIVzdG:2aX7pZi=> MYeyNlk6PDd6MB?=
MG-63 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLDN|AxKG6P M1T4S|EzKGh? Ml3JSG1UVw>? NGTPd45qdmirYnn0d{B1cGViY3XscEBoem:5dHigeI8hQDZn NELsT28zOjd7OUOzPC=>
MG-63 Ml70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDmUoVxOzByIH7N MYCyOEBp NYPoTIFLTE2VTx?= NEDncohqdmirYnn0d{B1cGViY3XscEBoem:5dHigeI8hPjdn M1fjXFIzPzl7M{O4
MG-63 Mm\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3XN|AxKG6P NU\MfpNjPDhiaB?= Mlu2SG1UVw>? Ml7TbY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIITvJFU3LQ>? MX2yNlc6QTN|OB?=
HL60  NY[2N5ZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYj0fZNzOTVyLUO1NEBvVQ>? NIj0VYEzPCCq MlvIbY5kemWjc3XzJINmdGxiYYDvdJRwe2m|wrD3bIVvKGOxbnPlcpRz[XSrb37zJIhq\2incjD0bIFvKDJ3MDDuUS=> M4e4UVIzPzV|N{O5
U937 NWLl[HNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUK5[HZjOTVyLUO1NEBvVQ>? M{PKUFI1KGh? MlHwbY5kemWjc3XzJINmdGxiYYDvdJRwe2m|wrD3bIVvKGOxbnPlcpRz[XSrb37zJIhq\2incjD0bIFvKDJ3MDDuUS=> M1v1VVIzPzV|N{O5
SCC-6 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHrNlAxNTN{MECgcm0> MkW3NVIwOjRxNEigbC=> NUL3NFJSTE2VTx?= NVSxdJh1cW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44hd2ZiU1PDMVYh[2WubIOgbY4h[SCmb4PlMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy MUWyNlU2OjN{MR?=
U87  NF\ocHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVSxNFAuOzByIH7n NFnB[5AzPCCq NX3LW|JUcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJJRwKDd{JTCgZZQhOjBybne= MlHiNlIzPzB6NEm=
K562 NVnOOW1GTnWwY4Tpc44hSXO|YYm= M2nGUFEh|ryP NIPpOmQyOiCq NYPOU|B6TE2VTx?= Mn3M[Y5p[W6lZYOgeIhmKGW6cILld5Nqd25ib3[gVnVPYDNiaX7keYNm\CCkeTC1MYF7[S2FZGK= NYewUllnOjJzN{mxPVg>
Reh NF;DRoVHfW6ldHnvckBCe3OjeR?= Mn7qNE4{NzFizszN NEHZSW8yOiCq MVvEUXNQ MlXT[Y5p[W6lZYOgeIhmKGW6cILld5Nqd25ib3[gVnVPYDNiaX7keYNm\CCkeTC1MYF7[S2FZGK= MlLsNlIyPzlzOUi=

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
EGFR / STAT3 ; 

PubMed: 31289542     


Expression of EGFR and STAT3 in PC3 cells treated with TSA. PC3 cells were plated in 6-cm dishes, and 0.25, 0.5 or 1 µM TSA was added for 24 h. DMSO was added into the control group wells. Cells were collected and lysed with lysis buffer and the protein expression analyzed via western blotting.

Cyclin D1 / CDK6 / CDK4 / p-RB / RB; 

PubMed: 31289542     


Expression of cyclin D1, CDK6, CDK4 and RB, and the phosphorylation of RB, was detected in PC3 cells treated with TSA for 24 h. 

MMP-1 / MMP-3 / MMP-13 / TIMP-1; 

PubMed: 27431944     


Chondrocytes were pretreated with increasing concentrations of TSA for 2 h, followed by stimulation with 5 ng/ml IL-1β for 24 h.

Acetyl-H3 (Lys27) / H3 (96C10) / Acetyl-H4(Lys8) / H4(L64C1); 

PubMed: 27431944     


Chondrocytes were treated with increasing concentrations of TSA for 24 h.

α-H3Ac / α-H4Ac / α-H3K9Ac / α-H3K9 S10 / α-H3K4 me / α-H3K4 me2 / α-H3K9 me2; 

PubMed: 23802098     


Histone acetylation occurs directly at the promoter region of IL-23R. The ChIP assay demonstrates that TSA treatment results in an increase in the acetylation of histone H3 and H4. A549 cells were cultured in the presence or absence of TSA (250 ng/mL) for a period of 24 h. Subsequently, a ChIP assay was performed using the following antibodies; pan acetyl-histone H3 (H3Ac), pan acetyl-histone H4 (H4Ac), acetyl-histone H3 Lys 9 (H3K9Ac), acetyl-histone H3 Lys 9/14 (H3K9/14ac), acetyl-histone H3 Lys 9 phosphoSer10 (H3K9S10), methyl-histone H3 Lys 4 (H3K4Me), di methyl-histone H3 Lys 4 (H3K4Me2), and di methyl-histone H3 Lys 9 (H3K9Me2). Input DNA serves as a positive control as recommended by the manufacturer (Diagenode). A no antibody control was included to test for non-specific binding (UT, untreated; TSA, Trichostatin A).

31289542 27431944 23802098
Immunofluorescence
α-C/EBPβ / α-HP1α ; 

PubMed: 21122806     


3T3-L1 preadipocytes were grown on coverslips for three days and induced to differentiate by treatment with MDI (48 h) in the presence of vehicle (-TSA) or 87 nM Trichostatin A (+TSA). Under these experimental conditions: A-H Cells were fixed and permeabilized in cold methanol, subjected to IIF with the indicated antibodies, and nuclei were counterstained with DAPI. Scale bar, 5 μm. 

α-HDAC1 ; 

PubMed: 29045501     


MCF-7 cells were treated with indicated concentrations of trichostatin A (optical sections E-H, respectively) for 12 hours, fixed, permeabilized and optical sections were obtained by laser scanning confocal microscopy. Fluorescence signal for HDAC1 is shown in green (left panels), DAPI staining is shown in blue (middle panels), and merged optical sections are shown in the right panels.

α-tubulin / acetylated histone 3; 

PubMed: 27957719     


Immunocytochemistry for acetylated α-tubulin (red) and acetylated histone 3 (green) on N2a cells treated with 1 μM TSA, ACY-738, and ACY-775.

21122806 29045501 27957719
Growth inhibition assay
Cell viability (A549 cells); 

PubMed: 27571418     


Cytotoxicity of histamine determined by MTT assay in A549 cells.

Cell viability (MDA-MB-231 cells); 

PubMed: 27548148     


The human breast cancer cells (MDA-MB-231) were incubated with various concentrations of TSA (0–300 nM) for 24 h. Cell viability was measured by WST-8.

Cell viability (PC3 cells); 

PubMed: 31289542     


PC3 cells were plated in a 96-well plate and treated with different doses of TSA (0, 0.25, 0.5 and 1 µM) for 72 h; an MTT assay was used to measure the effects of TSA on PC3 cell proliferation.

27571418 27548148 31289542
体内研究 Administration of Trichostatin A 按 0.5 mg/kg 剂量处理N-甲基-N-亚硝基脲致癌物诱发的大鼠乳腺癌模型，持续处理4周，具有有效的抗癌活性，即使按按高达5 mg/kg剂量处理也没有任何可测量到的毒性。[1]Trichostatin A 按10 mg/kg 剂量单独腹腔注射给药非转基因和脊髓性肌萎缩症（SMA）模型鼠，导致乙酰化的 H3 和 H4组蛋白水平提高，也导致活运动神经元(SMN) 基因表达稍微提高。Trichostatin A 每天按10 mg/kg剂量处理SMA模型鼠，促进存活, 减轻体重下降,且增强运动行为。[5]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验：[1]
- 合并

体外HDAC活性 :

从每种乳腺癌细胞系(MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51,或 SK-BR-3)中准备全部细胞提取物。在溶于0.1% (v/v)乙醇的不同浓度Trichostatin A存在时，或者使用0.1% (v/v)乙醇作为对照, 20 μL 细胞粗提取物(~2.5 ×105 个细胞)与 1 μL ~1.5 × 106 cpm [3H]乙酰标记的组蛋白 H4 肽底物(第2-20位NH2-末端残基) 在25oC下温育60分钟。使用50 μL 1 M HCl/0.16 M 乙酸对每组 200-μL 反应进行淬火，然后使用600 μL 乙酸乙酯进行抽提，通过闪烁计数器测量释放的[3H]乙酸。使用非线性回归曲线拟合抑制数据，绘制合适的剂量反应曲线，而测定IC50。
细胞实验：[1]
- 合并
  • Cell lines: MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, 和 SK-BR-3
  • Concentrations: 溶于无水酒精,终浓度为~10 μM
  • Incubation Time: 96小时
  • Method: 使用不同浓度Trichostatin A处理细胞96小时。处理后,使用sulforhodamine B 比色分析测定细胞增殖。通过台酚蓝染色排除法测定细胞活力。
    (Only for Reference)
动物实验：[1]
- 合并
  • Animal Models: 携带NMU诱导的肿瘤的近交系(Ludwig/Wistar/Olac)处女鼠
  • Formulation: 溶于DMSO
  • Dosages: ~5 mg/kg/day
  • Administration: 皮下注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 23 mg/mL (76.05 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)：
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
 3mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 302.4
化学式

C17H22N2O3
CAS号 58880-19-6
储存条件 粉状
溶于溶剂
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量：

总分子量：g/mol

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03901053 Not yet recruiting Device: Reaktiv AFO|Device: PhatBrace AFO Foot Injuries and Disorders Jason Wilken|Minneapolis Veterans Affairs Medical Center|Walter Reed National Military Medical Center|Henry M. Jackson Foundation for the Advancement of Military Medicine|Center for Veterans Research and Education|University of Delaware|Johns Hopkins Bloomberg School of Public Health|University of Iowa June 2019 Not Applicable
NCT03887650 Recruiting Drug: Liposomal Bupivicaine 1.3%|Drug: Bupivacaine 0.5% Post-operative Pain|Total Shoulder Arthroplasty|Osteoarthritis of the Shoulder|Pain Management Hartford Hospital January 14 2019 Phase 4
NCT03838926 Recruiting Drug: Trichostatin A Relapsed or Refractory Hematologic Malignancies Vanda Pharmaceuticals September 27 2018 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1：

    I would like to obtain the enantiomers of TSA, as separate chemicals: R-TSA and S-TSA. Do you have any ideas?

  • 回答：

    Our S1045 Trichostatin A (TSA) is R enantiomer.

Selleck产品目录册

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

相关HDAC产品

  • LMK-235 New

    LMK-235是HDAC4和HDAC5的选择性抑制剂， IC50分别为11.9 nM 和 4.2 nM。

  • CAY10603 New

    CAY10603是一种强效的选择性HDAC6抑制剂，IC50为2 pM，选择性比其它HDACs高200多倍。

  • Domatinostat (4SC-202) New

    4SC-202是一种选择性的I类HDAC抑制剂，对HDAC1，HDAC2，和HDAC3的IC50分别为1.20 μM，1.12 μM，和0.57 μM。也对Lysine specific demethylase 1 (LSD1)表现出抑制活性。Phase 1。

  • Panobinostat (LBH589)

    Panobinostat (LBH589)是一种新型的，广谱HDAC抑制剂，无细胞试验中IC50为5 nM。Phase 3。

  • Vorinostat (SAHA)

    Vorinostat (suberoylanilide hydroxamic acid, SAHA)是一种HDAC抑制剂，无细胞试验中IC50为~10 nM。

    Features:Vorinostat是广谱HDAC活性抑制剂，抑制I和II类酶 。

  • Entinostat (MS-275)

    Entinostat (MS-275)强烈抑制HDAC1和HDAC3，无细胞试验中IC50分别为0.51 μM和1.7 μM，抑制作用强于HDACs 4， 6， 8，和10。Phase 3。

  • Romidepsin (FK228, Depsipeptide)

    Romidepsin (FK228, Depsipeptide)是一种有效的HDAC1和HDAC2抑制剂，无细胞试验中IC50分别为36 nM和47 nM。

    Features:Romidepsin对I型HDAC的抑制作用明显强于对II型HDAC的抑制。

  • RGFP966

    RGFP966是一种HDAC3抑制剂，无细胞试验中IC50为0.08μM ，比作用于其他HDAC选择性高200倍以上。

  • Tubastatin A

    Tubastatin A是一种有效的，选择性HDAC6抑制剂，无细胞试验中IC50为15 nM，选择性远高于所有其他同工酶(1000倍)除了HDAC8(57倍)。

  • Mocetinostat (MGCD0103)

    Mocetinostat (MGCD0103)是一种有效的HDAC抑制剂，对HDAC1抑制作用最强，无细胞试验中IC50为0.15 μM，比作用于HDAC2， 3，和11选择性高2到10倍，对HDAC4， 5， 6， 7，和8没有抑制活性。Phase 2。

Tags: 购买Trichostatin A (TSA) | Trichostatin A (TSA)供应商 | 采购Trichostatin A (TSA) | Trichostatin A (TSA)价格 | Trichostatin A (TSA)生产 | 订购Trichostatin A (TSA) | Trichostatin A (TSA)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID